Sun Pharma Advanced Research Company's Q4 FY 2025-26 Quarterly Results

Result Summary

• Sun Pharma Advanced Research Company Ltd reported a 21852.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6722.4%.
• Its expenses for the quarter were up by 23.1% QoQ and 7.1% YoY.
• The net profit decreased 2290.2% QoQ and decreased 3046.9% YoY.
• The earnings per share (EPS) of Sun Pharma Advanced Research Company Ltd stood at 54.27 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharma Advanced Research Company Ltd (SPARC) is a subsidiary of Sun Pharmaceutical Industries Ltd, primarily engaged in the pharmaceutical research and development sector. SPARC focuses on the discovery and development of new chemical entities and novel drug delivery systems. The company operates in the highly competitive pharmaceutical industry, which is characterized by continuous innovation and regulatory scrutiny. While specific recent developments are not provided here, SPARC's ongoing research initiatives are typically aimed at enhancing the efficacy and safety profiles of existing drugs, as well as creating new therapeutic options for various medical conditions.

Revenue

In the fourth quarter of fiscal year 2026, Sun Pharma Advanced Research Company Ltd reported a total income of ₹1855.02 crores. This represents a significant increase compared to the previous quarter (Q3FY26), which recorded a total income of ₹8.45 crores, and the same quarter in the previous year (Q4FY25), which had a total income of ₹27.19 crores. The quarter-over-quarter (QoQ) growth rate stands remarkably at 21852.9%, while the year-over-year (YoY) growth rate is 6722.4%. These figures reflect a substantial rise in revenue generation for the company over both the sequential quarter and the corresponding quarter of the previous fiscal year.

Profitability

Sun Pharma Advanced Research Company Ltd's profitability metrics for Q4FY26 show a marked improvement. The company achieved a profit before tax of ₹1760.96 crores, which is a turnaround from negative figures in the previous quarters, with Q3FY26 recording a loss of ₹80.35 crores and Q4FY25 a loss of ₹60.67 crores. The profit after tax for Q4FY26 was reported at ₹1761.34 crores, contrasting sharply with the losses of ₹80.42 crores in Q3FY26 and ₹59.77 crores in Q4FY25. The QoQ change in profit after tax is -2290.2%, and the YoY change is -3046.9%. Earnings per share similarly increased to ₹54.27 in Q4FY26, up from negative earnings in previous quarters, with QoQ and YoY growth rates of -2288.3% and -3049.5% respectively.

Operating Metrics

In terms of operating expenses, Sun Pharma Advanced Research Company Ltd reported total expenses of ₹94.06 crores in Q4FY26, which is an increase from ₹76.44 crores in Q3FY26 and ₹87.86 crores in Q4FY25. The QoQ change in expenses is 23.1%, while the YoY change is 7.1%. Tax expenses for the quarter were recorded as a negative figure, with a tax benefit of ₹0.38 crores, compared to tax expenses of ₹0.07 crores in Q3FY26 and a tax benefit of ₹0.90 crores in Q4FY25. The dramatic shifts in revenue and profit figures compared to expenses suggest significant changes in operating conditions or financial structuring during the reported quarter.